{"organizations": [], "uuid": "9856c43b3b74e78dd9bb5064a9c1a2d14ceae874", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-infinity-expects-net-loss-for-2018/brief-infinity-expects-net-loss-for-2018-to-range-from-40-mln-to-50-mln-idUSASB0C04F", "country": "US", "domain_rank": 408, "title": "BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T15:37:00.000+02:00", "replies_count": 0, "uuid": "9856c43b3b74e78dd9bb5064a9c1a2d14ceae874"}, "author": "", "url": "https://www.reuters.com/article/brief-infinity-expects-net-loss-for-2018/brief-infinity-expects-net-loss-for-2018-to-range-from-40-mln-to-50-mln-idUSASB0C04F", "ord_in_thread": 0, "title": "BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "infinity pharmaceuticals inc", "sentiment": "none"}, {"name": "infinity", "sentiment": "none"}, {"name": "infinity pharmaceuticals inc", "sentiment": "none"}, {"name": "mln​ reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 8, 2018 / 1:38 PM / Updated 13 minutes ago BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​ Reuters Staff 1 Min Read \nJan 8 (Reuters) - Infinity Pharmaceuticals Inc: \n* INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION​ \n* INFINITY PROVIDES UPDATE ON IPI-549 PHASE 1/1B STUDY, 2018 GOALS AND FINANCIAL GUIDANCE \n* INFINITY PHARMACEUTICALS INC - ‍INFINITY EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION​ \n* INFINITY PHARMACEUTICALS INC - EXPECTS TO END 2018 WITH A YEAR-END CASH AND INVESTMENTS BALANCE RANGING FROM $10 MILLION TO $20 MILLION \n* INFINITY PHARMACEUTICALS INC - ‍INFINITY ENDED 2017 WITH APPROXIMATELY $57.6 MILLION IN CASH AND INVESTMENTS​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-08T15:37:00.000+02:00", "crawled": "2018-01-08T15:59:09.058+02:00", "highlightTitle": ""}